Cellect Biotechnology Ltd. (APOP) Stock Analysis
DELISTED 2021
What happened to Cellect Biotechnology Ltd. (APOP) stock?
Cellect Biotechnology Ltd. (APOP) no longer trades on public markets. It was delisted in October 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cellect Biotechnology Ltd. (APOP) trades at $13.17. Cellect Biotechnology Ltd. (APOP) is a biotechnology company specializing in cell therapies, particularly focusing on enhancing the safety and efficacy of bone marrow transplants. Market cap: $129M, Sector: Healthcare.
Last analyzed: Jun 15, 2026Analyst Coverage for APOP: APOP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APOP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Cellect Biotechnology Ltd. (APOP) Healthcare & Pipeline Overview
Cellect Biotechnology Ltd. (APOP) is a biotechnology firm dedicated to advancing cell therapy technologies, primarily aimed at improving bone marrow transplant outcomes, leveraging its specialized cell selection technology in a rapidly growing market.
What Is the Investment Thesis for APOP?
Cellect Biotechnology Ltd. (APOP) presents a unique investment thesis centered around its proprietary cell selection technology, which aims to enhance the safety and efficacy of bone marrow transplants. The global cell therapy market is projected to reach $8.5 billion by 2027, growing at a CAGR of 36.2%. Cellect's focus on this niche market positions it to capture significant market share, particularly as the demand for effective therapies increases. Key value drivers include successful clinical trial outcomes, potential partnerships with larger pharmaceutical companies, and advancements in regulatory approvals. However, risks include the inherent uncertainties of clinical trials and the need for ongoing funding to support its research initiatives. Investors should monitor the company's clinical progress and any strategic collaborations that may arise.
Based on FMP financials and quantitative analysis
APOP Key Highlights
Market Cap of $129M reflects a growing interest in cell therapy innovations.
- Beta of 1.88 indicates higher volatility compared to the broader market, suggesting potential for significant price movements.
- No dividend yield emphasizes the company's focus on reinvesting in research and development.
- Small employee base of 12 allows for nimble decision-making and rapid innovation.
- Specialized technology in cell selection positions Cellect in a unique niche within the biotechnology sector.
Who Are APOP's Competitors?
APOP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| EDIT Editas Medicine, Inc. | $2.94 | -9.54% | $451M | — |
| SGMO Sangamo Therapeutics, Inc. | $0.07 | +0.00% | $30.7M | — |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APOP's Key Strengths?
Innovative proprietary technology in cell selection.
- Focused expertise in cell therapies, particularly for bone marrow transplants.
- Agile organizational structure with a small team that can adapt quickly.
- Strong potential for partnerships with larger firms in the biotechnology sector.
What Are APOP's Weaknesses?
Limited financial resources due to a small market cap.
- Dependence on successful clinical trial outcomes for future growth.
- Small workforce may limit operational capabilities.
- Lack of established market presence compared to larger competitors.
What Could Drive APOP Stock Higher?
Results from ongoing clinical trials expected to be released in Q3 2026.
- Development of partnerships with larger pharmaceutical companies to enhance research capabilities.
- Anticipated regulatory submissions for new therapies in late 2026.
- Continuous refinement of proprietary technology to improve treatment outcomes.
- Expansion efforts into North American and European markets planned for 2026.
What Are the Key Risks for APOP?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High dependency on the success of clinical trials for product validation.
- Limited financial resources may hinder operational capabilities and growth.
- Regulatory challenges could delay product approvals and market entry.
- Competitive pressure from larger biotechnology firms may impact market share.
- Market volatility affecting investor confidence and funding availability.
What Are the Growth Opportunities for APOP?
- Expansion into New Markets: Cellect Biotechnology Ltd. aims to expand its presence in international markets, particularly in North America and Europe, where the demand for advanced cell therapies is increasing. The global cell therapy market was valued at approximately $5.6 billion in 2021 and is expected to grow at a CAGR of 36.2% through 2027. This expansion could significantly increase Cellect's market share and revenue streams.
- Technological Advancements: The company is continuously refining its proprietary cell selection technology, which could lead to improved outcomes in bone marrow transplants. As the technology matures, Cellect may enhance its product offerings, thereby attracting partnerships with larger pharmaceutical firms seeking innovative solutions in cell therapy.
- Strategic Partnerships: Establishing collaborations with major healthcare providers and research institutions can accelerate Cellect's clinical trials and product development. Such partnerships could provide access to additional funding and resources, essential for navigating the complex regulatory landscape in biotechnology.
- Regulatory Approvals: Successful navigation of the regulatory process for its cell therapy products is crucial. Gaining approvals from regulatory bodies such as the FDA can open up significant market opportunities, allowing Cellect to commercialize its innovative therapies and generate revenue.
- Increased Investment in R&D: As the biotechnology sector continues to attract investment, Cellect's focus on innovative cell therapies could position it favorably for funding opportunities. Increased investment in research and development can enhance its technological capabilities and expedite the development of new therapies.
What Are APOP's Competitive Advantages?
- Proprietary cell selection technology that enhances the efficacy of therapies.
- Specialization in a niche market of cell therapies, reducing direct competition.
- Strong focus on research and development, fostering innovation.
- Established relationships with research institutions for collaborative advancements.
- Potential for strategic partnerships with larger pharmaceutical companies to enhance market access.
What Does APOP Do?
Cellect Biotechnology Ltd. was founded with the vision of transforming the field of cell therapies through innovative technology that enhances the selection and efficacy of therapeutic cells. Headquartered in Kfar Saba, Israel, the company has developed a proprietary platform designed to improve the safety and effectiveness of bone marrow transplants, a critical procedure for patients with various hematological conditions. Over the years, Cellect has focused on refining its technology to ensure that it meets the stringent demands of the healthcare sector. With a small team of 12 employees, the company is agile and able to adapt quickly to the evolving landscape of biotechnology. Cellect's flagship technology is expected to play a significant role in optimizing cell therapies, which are increasingly recognized for their potential to treat a wide range of diseases. The company operates primarily within the global biotechnology market, which is projected to grow significantly as demand for advanced medical treatments rises. Cellect Biotechnology's commitment to innovation positions it favorably in a competitive environment, where it seeks to establish partnerships and collaborations that can further its research and development efforts.
What Products and Services Does APOP Offer?
- Develop cell therapies aimed at improving patient outcomes in bone marrow transplants.
- Utilize proprietary technology for cell selection to enhance the safety and efficacy of treatments.
- Conduct clinical trials to validate the effectiveness of its therapies.
- Collaborate with research institutions to advance cell therapy innovations.
- Focus on regulatory compliance to ensure successful product approvals.
- Engage in strategic partnerships to expand market reach and resource access.
How Does APOP Make Money?
- Generate revenue through the development and commercialization of innovative cell therapies.
- Leverage partnerships with pharmaceutical companies for co-development and licensing agreements.
- Seek funding through grants and investments to support research and development initiatives.
- Conduct clinical trials to establish the efficacy of its therapies, paving the way for market entry.
- Utilize proprietary technology to differentiate its offerings in the competitive biotechnology landscape.
What Industry Does APOP Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in cell and gene therapies. The global cell therapy market is expected to grow significantly, with increasing investments in research and development. Cellect Biotechnology Ltd. operates within this dynamic environment, focusing on cell selection technologies that enhance treatment outcomes for patients undergoing bone marrow transplants. Competitive pressures are high, with numerous players vying for market share, but Cellect's specialized technology provides a differentiated offering that could lead to strategic partnerships and collaborations.
Who Are APOP's Key Customers?
- Healthcare providers and hospitals seeking advanced treatment options for patients requiring bone marrow transplants.
- Pharmaceutical companies interested in collaborative development of cell therapies.
- Research institutions focused on innovative healthcare solutions.
- Investors looking for opportunities in the biotechnology sector.
- Patients and advocacy groups seeking improved treatment outcomes in hematological conditions.
Company Profile
Cellect Biotechnology Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kfar Saba, IL. The company is led by CEO Shai Yarkoni. APOP has traded publicly since 2016.
Cellect Biotechnology Ltd. (APOP) Valuation Context
Valued at $129M, APOP is classified as a micro-cap stock.
Key Financial Metrics
A current ratio of 2.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -184.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Cellect Biotechnology Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.57 places it in the safe zone, indicating low near-term bankruptcy risk.
APOP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Cellect's pipeline, indicating that executives believe in the company's future prospects.
- Community sentiment has been increasingly positive, with discussions highlighting the potential of their innovative therapies.
- Recent partnerships and collaborations have sparked interest, enhancing the company's market visibility and credibility.
- The ongoing advancements in their clinical trials have generated excitement, positioning Cellect as a player in the regenerative medicine space.
Bear Case
- Concerns about the competitive landscape in biotechnology may dampen enthusiasm, as rivals are also advancing their own therapies.
- Recent social sentiment reflects skepticism regarding the company's ability to meet regulatory hurdles, which could delay product launches.
- Market perception remains cautious due to historical volatility in biotech stocks, leading to hesitance among potential investors.
- Insider selling activity in the past has raised red flags, suggesting that some insiders may lack confidence in the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
APOP Latest News
No recent news available for APOP.
Leadership: Shai Yarkoni
CEO
Shai Yarkoni has a robust background in biotechnology and management, bringing extensive experience to Cellect Biotechnology Ltd. He has held various leadership roles in the healthcare sector, focusing on innovative therapies and strategic growth. His educational background includes degrees in relevant fields, equipping him with the knowledge necessary to lead a biotechnology firm effectively.
Track Record: Under Shai Yarkoni's leadership, Cellect has made significant strides in developing its proprietary cell selection technology and advancing clinical trials. His strategic vision has positioned the company to explore partnerships that can enhance its market presence and technological capabilities.
Cellect Biotechnology Ltd. ADR Information Sponsored
An American Depositary Receipt (ADR) is a negotiable certificate representing shares in a foreign company's stock, allowing U.S. investors to trade shares without dealing with foreign currencies. Cellect Biotechnology Ltd. (APOP) operates as a Level II ADR, which provides a higher level of disclosure and reporting compared to Level I.
- Home Market Ticker: Tel Aviv Stock Exchange, Israel
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About APOP (Healthcare)
What happened to Cellect Biotechnology Ltd. (APOP) stock?
Cellect Biotechnology Ltd. (APOP) no longer trades on public markets. It was delisted in October 2021. The figures below are historical and are not a current quote.
Can I still buy APOP shares?
No. APOP stopped trading on public markets in October 2021, so the shares are not available through a broker. Anything you see quoted for APOP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before APOP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Cellect Biotechnology Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Cellect Biotechnology Ltd. do?
Cellect Biotechnology Ltd. specializes in developing innovative cell therapies, particularly focusing on enhancing the safety and efficacy of bone marrow transplants. Through its proprietary cell selection technology, the company aims to improve patient outcomes in hematological conditions. Cellect is engaged in clinical trials to validate its therapies and seeks to establish partnerships to further its research and development efforts.
What are the key growth opportunities for APOP in healthcare?
Cellect Biotechnology Ltd. has several growth opportunities, including expanding its presence in international markets where the demand for advanced cell therapies is increasing. The global cell therapy market is projected to grow significantly, offering Cellect a chance to capture market share. Additionally, strategic partnerships with larger pharmaceutical companies can enhance its research capabilities and expedite product development.
What are the main risks for APOP?
Cellect Biotechnology Ltd. faces several risks, including a high dependency on the success of clinical trials, which are crucial for validating its therapies. The company also has limited financial resources, which may hinder its operational capabilities and growth. Furthermore, regulatory challenges could delay product approvals, and competitive pressures from larger biotechnology firms may impact its market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on the latest available data and may be subject to change as new developments occur.